Alpha thymosin peptides as cancer vaccine adjuvants

Details Alpha thymosin peptides as cancer vaccine adjuvants Alpha thymosin peptides as cancer vaccine adjuvants

A - Human Necessities

61

K

A61K 39/00 (2006.01)

Patent

CA 2588685

A pharmaceutical combination and method for enhancing cancer vaccine effectiveness in a subject, utilize an immune response-triggering cancer vaccine capable of eliciting an immune system response in a subject, and a vaccine effectiveness-enhancing amount of an alpha thymosin peptide, which enhances the immune system response in the subject, wherein the cancer vaccine and the alpha thymosin peptide can be administered separately or together.

Combinaison pharmaceutique et méthode permettant de renforcer l'efficacité d'un vaccin anti-cancéreux chez un sujet. Cette combinaison/méthode fait appel à un vaccin anti-cancéreux déclenchant une réponse immunitaire qui élicite une réaction du système immunitaire, et à une dose renforçant l'efficacité du vaccin d'un peptide d'alpha-thymosine. Le vaccin anti-cancéreux et le peptide d'alpha thymosine peut être administrés séparément ou ensemble.

Affiliated with

Also associated with

Rating

Alpha thymosin peptides as cancer vaccine adjuvants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Alpha thymosin peptides as cancer vaccine adjuvants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha thymosin peptides as cancer vaccine adjuvants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1542796